Category

• Pipeline3

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• FDA2
• Clinical Trials2
• Retina2
• AMD1
• Crispr1
• Anti-vegf1
• Gene Therapy1
• Inherited Retinal Disease1
• Wet Amd1

• Organizations: HuidaGene Therapeutics✕

Clear all

Pipeline

FDA clears HuidaGene's IND for CRISPR RNA-editing nAMD therapy

HG202 is now the only clinical-stage RNA-targeting therapy in clinical development for nAMD, with an upcoming phase 1 trial slated for Q2 2025.

Pipeline

FDA grants HuidaGene's HGOO4 rare pediatric disease designation to treat IRD

Novel injectable therapy for RPE65 retinopathies given green light to move forward through FDA review process.

Pipeline

FDA grants ODD to HuidaGene’s IRD gene therapy

Multinational trial will assess HG004 for adult and pediatric patients with IRDs linked to RPE65 mutations.